Skip to content
Flecainide
Tambocor (flecainide) is a small molecule pharmaceutical. Flecainide was first approved as Tambocor on 1985-10-31. It is used to treat atrial fibrillation, cardiac arrhythmias, supraventricular tachycardia, and ventricular tachycardia in the USA. It is known to target potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 1, potassium voltage-gated channel subfamily A member 2, and potassium voltage-gated channel subfamily C member 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flecainide acetate
Tradename
Company
Number
Date
Products
TAMBOCORAlvogenN-018830 DISCN1985-10-31
4 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
flecainide acetateANDA2023-05-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
cardiac arrhythmiasEFO_0004269D001145I49.9
supraventricular tachycardiaHP_0004755D013617I47.1
ventricular tachycardia—D017180I47.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BC: Antiarrhythmics, class ic
— C01BC04: Flecainide
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R52———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFLECAINIDE
INNflecainide
Description
Flecainide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of piperidines, an organofluorine compound and an aromatic ether. It is a conjugate base of a flecainide(1+).
Classification
Small molecule
Drug classIc antiarrhythmic
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
Identifiers
PDB6MVX
CAS-ID54143-55-4
RxCUI4441
ChEMBL IDCHEMBL652
ChEBI ID75984
PubChem CID3356
DrugBankDB01195
UNII IDK94FTS1806 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNA7
KCNA7
KCNA5
KCNA5
KCNA1
KCNA1
KCNA2
KCNA2
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
KCNA7
Gene synonyms
NCBI Gene ID
3743
Protein name
potassium voltage-gated channel subfamily A member 7
Protein synonyms
potassium channel, voltage gated shaker related subfamily A, member 7, potassium voltage-gated channel, shaker-related subfamily, member 7, voltage-dependent potassium channel Kv1.7, voltage-gated potassium channel KCNA7, Voltage-gated potassium channel subunit Kv1.7
Uniprot ID
Q9BYS4
Mouse ortholog
Kcna7 (16495)
potassium voltage-gated channel subfamily A member 7 (Q17ST2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,911 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
79 adverse events reported
View more details